MDM2 and neuroblastoma: Even though several MDM2 inhibitors have already been tested in preclinical models of neuroblastoma and MDM2 validated as a promising target, the need remains to identify, develop and preclinically assess novel MDM2 inhibitors with greater efficacy, improved bioavailability and fewer toxic side effects.